Maze Therapeutics (MAZE) Equity Average (2024 - 2026)

Maze Therapeutics has disclosed Equity Average across 3 years of filings, most recently posting $348.3 million for Q1 2026.

• Equity Average for Q1 2026 came in at $348.3 million, up 3744.61% year-over-year; the trailing twelve-month figure through Mar 2026 was $348.3 million (up 3744.61% YoY), and the FY2025 annual result was $21.9 million, changed N/A from the prior year.
• Equity Average came in at $348.3 million for Q1 2026 at Maze Therapeutics, down from $367.2 million in the prior quarter.
• In the past five years, Equity Average ranged from a high of $367.2 million in Q4 2025 to a low of -$333.0 million in Q2 2024.
• The 3-year median for Equity Average is $133.8 million (2025), against an average of $50.0 million.
• Across the five-year window, Equity Average soared 183.23% in 2025 and soared 3744.61% in 2026, its largest moves.
• Maze Therapeutics' Equity Average stood at -$297.9 million in 2024, then jumped by 223.28% to $367.2 million in 2025, then dropped by 5.14% to $348.3 million in 2026.
• The last three Equity Average figures came in at $348.3 million (Q1 2026), $367.2 million (Q4 2025), and $320.8 million (Q3 2025), per Business Quant data.